Impact of Continuous Erythropoietin Receptor Activator on Selected Biomarkers of Cardiovascular Disease and Left Ventricle Structure and Function in Chronic Kidney Disease

Overview

Journal Oxid Med Cell Longev

Publisher Wiley

Specialties Cell Biology
Endocrinology

Date 2016 Apr 2

PMID 27034745

Authors

Piotr Bartnicki

Jacek Rysz

Beata Franczyk

Zbigniew Baj

Ewa Majewska

Affiliations

Soon will be listed here.

Abstract

Background. Cardiovascular morbidity and mortality are very high in patients with chronic kidney disease (CKD). The purpose of this study is to evaluate the impact of continuous erythropoietin receptor activator (CERA) on selected biomarkers of cardiovascular disease, left ventricle structure, and function in CKD. Material and Methods. Peripheral blood was collected from 25 CKD patients before and after CERA treatment and 20 healthy subjects. In serum samples, we assessed inflammatory markers (IL-1β, TNF-RI, TNF-RII, sFas, sFasL, MMP-9, TIMP-1, and TGF-β1), endothelial dysfunction markers (sE-selectin, sICAM-1, and sVCAM-1), and volume-related marker (NT-proBNP). All subjects underwent echocardiography and were evaluated for selected biochemical parameters (Hb, creatinine, and CRP). Results. Evaluated biomarkers and echocardiographic parameters of left ventricle structure were significantly increased but left ventricle EF was significantly decreased in CKD patients compared to controls. After CERA treatment, we observed a significant increase of Hb and left ventricle EF and a significant decrease of NT-proBNP and MMP-9. There was a significant negative correlation between Hb and TNF-RI, sICAM-1, and IL-1β. Conclusions. Our results indicate that selected biomarkers related to cardiovascular risk are significantly increased in CKD patients compared to controls. CERA treatment has anti-inflammatory action, diminishes endothelial dysfunction, and improves left ventricle function in these patients.

References

Garlanda C, Dinarello C, Mantovani A . The interleukin-1 family: back to the future. Immunity. 2013; 39(6):1003-18. PMC: 3933951. DOI: 10.1016/j.immuni.2013.11.010. View

Tanaka Y, Joki N, Hase H, Iwasaki M, Ikeda M, Ando R . Effect of erythropoietin-stimulating agent on uremic inflammation. J Inflamm (Lond). 2012; 9(1):17. PMC: 3787853. DOI: 10.1186/1476-9255-9-17. View

Bartnicki P, Majewska E, Kowalczyk M, Baj Z, Banach M, Rysz J . Impact of anemia treatment with methoxy polyethylene glycol-epoetin beta on polymorphonuclear cells apoptosis in predialysis patients with chronic kidney disease. Pharmacol Rep. 2015; 67(5):842-5. DOI: 10.1016/j.pharep.2015.01.014. View

Higuchi T, Fukuda N, Yamamoto C, Yamazaki T, Oikawa O, Ohnishi Y . The influence of uremic serum on interleukin-1beta and interleukin-1 receptor antagonist production by peripheral blood mononuclear cells. Ther Apher Dial. 2006; 10(1):65-71. DOI: 10.1111/j.1744-9987.2006.00346.x. View

Pozzoni P, Pozzi M, Del Vecchio L, Locatelli F . Epidemiology and prevention of cardiovascular complication in chronic kidney disease patients. Semin Nephrol. 2004; 24(5):417-22. DOI: 10.1016/j.semnephrol.2004.06.012. View

Chatterjee P . Pleiotropic renal actions of erythropoietin. Lancet. 2005; 365(9474):1890-2. DOI: 10.1016/S0140-6736(05)66622-6. View

Massy Z, Stenvinkel P, Drueke T . The role of oxidative stress in chronic kidney disease. Semin Dial. 2009; 22(4):405-8. DOI: 10.1111/j.1525-139X.2009.00590.x. View

Tabibi H, Ashabi A, Mahdavi-Mazdeh M, Hedayati M, Nozary-Heshmati B . Comparison of novel risk factors for cardiovascular disease between hemodialysis patients with and without protein-energy wasting. Int Urol Nephrol. 2014; 46(10):2015-20. DOI: 10.1007/s11255-014-0750-x. View

Tucker P, Scanlan A, Dalbo V . Chronic kidney disease influences multiple systems: describing the relationship between oxidative stress, inflammation, kidney damage, and concomitant disease. Oxid Med Cell Longev. 2015; 2015:806358. PMC: 4377508. DOI: 10.1155/2015/806358. View

10.

Martin-Ventura J, Blanco-Colio L, Munoz-Garcia B, Gomez-Hernandez A, Arribas A, Ortega L . NF-kappaB activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability. Stroke. 2004; 35(2):458-63. DOI: 10.1161/01.STR.0000114876.51656.7A. View

11.

Sato M, Konuma T, Yanagisawa N, Haizuka H, Asakura H, Nakashima Y . Fas-Fas ligand system in the peripheral blood of patients with renal diseases. Nephron. 2000; 85(2):107-13. DOI: 10.1159/000045642. View

12.

Yao Q, Pecoits-Filho R, Lindholm B, Stenvinkel P . Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol. 2005; 38(5):405-16. DOI: 10.1080/00365590410031715. View

13.

Silverberg D, Wexler D, Iaina A, Schwartz D . The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions. Clin Exp Nephrol. 2008; 13(2):101-106. DOI: 10.1007/s10157-008-0074-1. View

14.

Gupta J, Mitra N, Kanetsky P, Devaney J, Wing M, Reilly M . Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol. 2012; 7(12):1938-46. PMC: 3513744. DOI: 10.2215/CJN.03500412. View

15.

Sarnak M, Levey A, Schoolwerth A, Coresh J, Culleton B, Hamm L . Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and.... Hypertension. 2003; 42(5):1050-65. DOI: 10.1161/01.HYP.0000102971.85504.7c. View

16.

Choi J, Yang C, Kim Y, Joo K, Yoo T, Lee K . Effect of conversion from ESA with shorter half-life to CERA once monthly for maintaining Hb concentration in pre-dialysis CKD patients. Kidney Blood Press Res. 2013; 37(4-5):259-68. DOI: 10.1159/000350151. View

17.

Blanco-Colio L, Martin-Ventura J, de Teresa E, Farsang C, Gaw A, Gensini G . Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. Arterioscler Thromb Vasc Biol. 2006; 27(1):168-74. DOI: 10.1161/01.ATV.0000250616.26308.d7. View

18.

Wison S, Foo K, Cunningham J, Cooper J, Deaner A, Knight C . Renal function and risk stratification in acute coronary syndromes. Am J Cardiol. 2003; 91(9):1051-4. DOI: 10.1016/s0002-9149(03)00147-4. View

19.

Herzog C, Asinger R, Berger A, Charytan D, Diez J, Hart R . Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011; 80(6):572-86. DOI: 10.1038/ki.2011.223. View

20.

Bellinghieri G, Condemi C, Saitta S, Trifiro G, Gangemi S, Savica V . Erythropoiesis-stimulating agents: dose and mortality risk. J Ren Nutr. 2014; 25(2):164-8. DOI: 10.1053/j.jrn.2014.10.012. View